175696-50-1

Usage

Uses

Used in Pharmaceutical Industry:
N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine is used as an antifungal agent for its ability to inhibit the growth of various fungi. Its application in the pharmaceutical industry is primarily focused on the development of antifungal medications to treat fungal infections.
Used in Agricultural Industry:
In the agricultural industry, N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine is used as a biopesticide to protect crops from fungal infections. Its antifungal properties help in reducing the incidence of crop diseases caused by fungi, thereby improving crop yield and quality.
Used in Cosmetics Industry:
N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine is also utilized in the cosmetics industry as an ingredient in antifungal and antimicrobial products. Its incorporation in skincare and personal care products helps in maintaining hygiene and preventing fungal infections, especially in areas prone to moisture and warmth.
Used in Research and Development:
Due to its unique chemical properties and antifungal activity, N-tert-Butyloxycarbonyl-D-ribo-phytosphingosine is employed in research and development for the discovery of new antifungal drugs and therapies. It serves as a valuable compound for studying the mechanisms of action against various fungal pathogens and for the development of novel treatment strategies.

Upstream product

• 102308-32-7 (4S)-4-formyl-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 1944-80-5 pentadecyltriphenylphosphonium bromide 
• 124127-36-2 (S)-tert-butyl 4-[(1S,2R)-1,2-dihydroxyhexadecyl]-2,2-dimethyloxazolidine-3-carboxylate 
• 1332640-34-2 (R)-1-{(4R,5S)-5-[(S)-1-(benzylamino)allyl]-2,2-dimethyl-1,3-dioxolan-4-yl}-2-(tert-butyldimethylsilyloxy)ethanol 
• 1429195-22-1 C₂₇H₅₁NO₇ 
• 554-62-1 D-ribo-phytosphingosine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3144-09-0 methanesulfonamide 
• 214556-61-3 (2R,3Z)-2-(tert-butoxycarbonyl)amino-3-octadecen-1-ol 
• 122709-20-0 N-(tert-butoxycarbonyl)-L-serine N'-methoxy-N'-methylamide 
• 122709-21-1 (4S)-2,2-Dimethyl-4-(N-methoxy-N-methylcarbamoyl)oxazolidin-3-carbonsaeure-(tert-butyl)ester 
• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 629-72-1 pentadecyl bromide 
• 1332640-41-1 (2S,3S,4r,Z)-2-(benzylamino)octadec-5-ene-1,3,4-triol 

Downstream Products

• 116467-63-1 N-tert-butyloxycarbonylsphingosine 
• 1224436-76-3 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-diol 
• 1340475-39-9 tert-butyl ((2S,3S,4R)-3,4-dihydroxy-1-(trityloxy)octadecan-2-yl)carbamate 
• 1340475-40-2 (4S,5S)-5-((R)-1-hydroxypentadecyl)-4-(trityloxymethyl)oxazolidin-2-one 
• 1262283-63-5 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxo-6-tetradecyl-1,3-oxazinan-5-yl trifluoromethanesulfonate 
• 1262283-61-3 (R)-1-((4S,5R)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxooxazolidin-5-yl)pentadecyl methanesulfonate 
• 1262283-60-2 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-2-oxo-6-tetradecyl-1,3-oxazinan-5-yl methanesulfonate 
• 1262283-59-9 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-diol dimethanesulfonate 
• 1262283-55-5 (4S,5S,6S)-4-((tert-butyldiphenylsilyloxy)methyl)-5-hydroxy-6-tetradecyl-1,3-oxazinan-2-one 
• 1262283-54-4 (4S,5R)-4-((tert-butyldiphenylsilyloxy)methyl)-5-((R)-1-hydroxypentadecyl)oxazolidin-2-one 
• 1262283-52-2 (2S,3S,4R)-1-(tert-butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-3,4-cyclic sulfate 
• 1262283-53-3 C₃₉H₆₃NO₆SSi 
• 898531-99-2 (2S,3S,4R)-1-O-(6-deoxy-6-acetamido-α-D-galactopyranosyl)-2-(N-nervonoylamino)-1,3,4-octadecanetriol 
• 1089188-04-4 (2S,3S,4R)-1-O-(6-deoxy-6-phenylaminocarbonylamino-α-D-galactopyranosyl)-2-[(N-hexacosanoyl)amino]octadecane-3,4-diol 

Relevant academic research and scientific papers

A practical and scalable synthesis of KRN7000 using glycosyl iodide as the glycosyl donor

KRN7000 is particularly useful because it is a powerful and specific CD1d agonist and has prompted intense interest in the context of immunology in the past 25 years. Its limited commercial availability and high price has led to the publication of many different syntheses. However, almost all of them focused on the methodology development rather than a scalable synthesis. Herein, we have described a practical and scalable procedure for the synthesis of KRN7000 basing on the glycosyl iodide method. This procedure involves total of eight steps to obtain the highly pure product KNR7000 on gram scale from the commercially available starting materials (d-galactose and the phytosphingosine) with only three column chromatographic purifications.

New synthetic thiocolchicine derivatives as low-toxic anticancer agents

New thiocolchicine derivatives (1-8) were designed as less toxic anticancer agents possessing the powerful anticancer activity of colchicine. The synthesis and biological evaluation of these compounds were described. As a preliminary result of biological in vitro investigation, compounds 1, 6, and 7 showed lower toxicities than that of colchicine in combination with potent anticancer activities.

4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTICS COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

NOVEL PHYTOSPHINGOSINE-1-PHOSPHATE DERIVATIVE, PREPARATION METHOD THEREFOR, AND COMPOSITION FOR PREVENTING AND TREATING HAIR LOSS OR FOR GROWING HAIR COMPRISING SAME

The present invention provides: O-cyclic phytospingosine-1-phosphate (0-C-P1P), N-cyclic phytospingosine-1-phosphate (N-C-P1P), a pharmaceutically acceptable salt thereof, or a solvate thereof; a preparation method therefor; a cosmetic composition comprising the same for preventing hair loss or for growing hair; and a pharmaceutical composition for preventing and treating hair loss or for growing hair.

PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3

The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.